Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:40:31.704Z.
Calculation as of: 2026-10-06T19:40:31.704Z.
Quote observation: 2026-10-06T19:39:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$63.47M
Price/FCF Ratio
N/A
TTM Avg
47.92
3Y Avg
47.92
5Y Avg
47.92
Market Cap
$61.99M
Price/FCF Ratio
N/A
TTM Avg
1.90
3Y Avg
1.90
5Y Avg
1.90
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $63.56M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.47M | N/A | 47.92 | 47.92 | 47.92 |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.57 | 6.78 | 6.78 | 131.43 |
| RenovoRx, Inc. (RNXT)vs › | $62.17M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $61.99M | N/A | 1.90 | 1.90 | 1.90 |
| iBio, Inc. (IBIO)vs › | $65.59M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.62M | N/A | 35.77 | 35.77 | 35.77 |
| XBiotech Inc. (XBIT)vs › | $66.01M | N/A | 4.54 | 4.54 | 4.54 |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $66.47M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
